Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3605 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

New data supports Merck HIV drug

The results also showed that Isentress dosed at 200mg, 400mg, 600mg orally twice daily in combination with optimized background therapy (OBT) was generally well tolerated in these patients.

Bristol-Myers takes psoriasis drug into Phase II

The multi-centered randomized, double-blind, placebo-controlled trial, will examine the safety and efficacy of BMS 582949 at three different doses. Approximately 100 patients are expected to be enrolled in

LigoCyte and Biogen to develop anti-CD103 therapies

Under the agreement, LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for co-development, co-promotion, and sharing of profits resulting